PTR 709 A
Alternative Names: PTR 709Latest Information Update: 03 Feb 2017
At a glance
- Originator Peptor
- Class
- Mechanism of Action Peptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 03 Feb 2017 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 03 May 2004 Suspended - Preclinical for Atherosclerosis in USA (unspecified route)
- 14 Jul 2003 Profile updated with data presented at the 10th Annual Meeting of the Biotechnology Industry Organization (BIO-2003)